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Background: Osteoradionecrosis (ORN) defines exposed irradiated bone, which fails to heal over a period of
3–6 months without evidence of residual or recurrent tumor. In the previous decades, a staging and treatment
protocol suggested by Marx, has dominated the approach to ORN. However, recently this paradigm is shifting. The
purpose of this study was to evaluate our institutional experience in managing ORN through a retrospective review
of case series from a large urban academic cancer centre.
Methods: A retrospective chart review was conducted to include all ORN cases from 2003 to 2009 diagnosed at
the Department of Otolaryngology – Head and Neck Surgery and the Department of Dentistry. The staging of ORN
was assessed as affected by tumor site, tumor stage, radiotherapy modality and dose, chemotherapy, dental work,
and time to diagnosis. The effectiveness of hyperbaric oxygen therapy (HBO) and surgery in the management of
ORN was evaluated.
Results: Fourteen cases of ORN were documented (incidence 0.84%). Primary subsites included tonsils, tongue,
retromolar trigone, parotid gland, soft palate and buccal mucosa. There were 5 (35.7%) stage 1, 3 (21.4%) stage 2,
and 6 (42.9%) stage 3 cases. ORN severity was not significantly associated with gender, smoking, alcohol use, tumor
site, T stage, N stage, AJCC stage, or treatment modality (radiation alone, surgery with adjuvant radiation or
adjuvant chemoradiation). Patients treated with intensity-modulated radiotherapy developed less severe ORN
compared to those treated with conventional radiotherapy (p < 0.015). ORN stage did not correlate with radiation
dose. In one patient only dental procedures were performed following radiation and could be implicated as the
cause of ORN. HBO therapy failed to prevent ORN progression. Surgical treatment was required for most stage 2
(partial resections and free tissue transfers) and stage 3 patients (mandibulectomies and free tissue transfers,
including two flaps in one patient). At an average follow up of 26 months, all patients were cancer-free, and there
was no evidence of ORN in 84% of patients.
Conclusions: In early ORN, we advocate a conservative approach with local care, while reserving radical resections
with robust reconstruction with vascularized free tissue for advanced stages.
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Osteoradionecrosis (ORN) is defined as exposed irradi-
ated bone that fails to heal over a period of 3 months
without a residual or recurrent tumor [1]. Some of the
signs and symptoms include pain, drainage, fistulization
to mucosa or skin, trismus, malocclusion, swelling, and
food impaction. There is an ongoing argument about the
exact definition of ORN, and specifically about timing,
radiographic and histologic features determining the
diagnosis [2].
In 1983, Marx proposed a theory of pathogenesis of
ORN, in conjunction with a staging system and a
management algorithm [3]. He implicated the role of
radiation-induced hypocellularity, hypovascularity, and
hypoxia as leading factors in the development of ORN.
Recently, the proposition of the fibroathropic theory
does not only imply atrophy of cellular components
forming the bone, but also activation of the fibroblastic
lineage, with eventual replacement of tissue with abnor-
mal myofibroblasts, resulting in ORN [4].
The clinical risk factors of ORN can be divided into
local and systemic. Some of the local factors include
tumor stage, tumor site, dose or radiation (>50-60 Gy),
radiation field, dental extraction and poor oral hygiene,
whereas systemic factors include infection, immune
deficient states, co-morbidities and malnutrition.
Despite challenges to Marx’s theories, his staging
system is still widely accepted. Stages 1 disease includes
exposed alveolar bone without signs of pathologic
fracture, which responds to hyperbaric oxygen (HBO)
therapy. Stage 2 disease does not respond to HBO, and
requires sequestrectomy and saucerization, whereas
stage 3, which involves full thickness bone damage or
pathologic fracture, usually requires complete resection
and reconstruction with free tissue.
In 2004, a French multicentre randomized, double-
blind, placebo-controlled trial demonstrated no benefit
of HBO treatment [5]. There were no significant dif-
ferences in terms of ORN recovery, time to treatment
failure and time to pain relief. In none of the outcome
measures did HBO outperform placebo. Interestingly,
this study was stopped at the second interim analysis
after showing potentially worse outcomes for HBO.
In addition, a recent review showed a lack of higher
levels of evidence in ORN studies, and questioned the
usefulness of HBO therapy, suggesting reserving it to
early stage disease only [6] While HBO remains a part of
the treatment scheme, surgical treatment has come to
the forefront of the management of advanced ORN.
Aggressive surgical resection of all diseased hard and
soft tissue and immediate reconstruction with free tissue
transfer has been suggested for stage 3 disease [7].
The rationale of the present study was to summarize
the institutional experience with the management ofORN at a large urban cancer centre, emphasizing the
early and aggressive surgical treatment employed to
prevent the progression of ORN.
Methods
A retrospective chart review was conducted on patients
presenting with ORN to the Department of Otolaryngo-
logy – Head and Neck Surgery and the Department of
Dentistry at a large urban cancer centre. This study was
approved by the institutional Research Ethics Board. All
head and neck cancer patient diagnosed and treated
from ORN from January of 2003 until December of 2009
were included in this study. The documented patient char-
acteristics included: gender, age, tobacco and alcohol
consumption, and Karnofsky Performance Status. Clinical
parameters included: primary site, TNM and AJCC disease
stage, pathological diagnosis, initial treatment (surgery,
radiation, chemotherapy, or a combination), time from
radiation to ORN, radiation modality and dose, pre-
radiation and post-radiation dental treatments, use of
hyperbaric oxygen therapy, as well as frequency and type
of surgical procedures used in ORN management. ORN
stage was classified according to Marx’s criteria [3].
The HBO protocol involved dives of 100% oxygen for
90 minutes under either 2.4 or 2.0 atmospheres of
pressure. It included 30 dives preoperatively and 10 dives
postoperatively for diagnosed ORN cases. Twenty pre-
operative dives were used for prophylaxis prior to elective
surgery on irradiated patients at risk, i.e. dental extractions
in the irradiated field. HBO therapy was never used alone
as a treatment modality, but as an adjunct to surgical
debridement.
Follow up was documented from the clinic notes and
included tumor recurrence and ORN resolution. It was
available for 92.9% of patients.
Statistical analysis was performed using SPSS for Mac
(Version 19.0, IBM Corp., Somers, NY). Chi-square test
was used for categorical data. One-way ANOVA with
Tukey’s multiple comparisons test was used for conti-




During the interval of the study (7 years) 1575 patients
were treated with radiation for head and neck cancer.
During the same time frame, 14 patients were treated
for ORN, with the ORN incidence rate of 0.89%
(Table 1). The majority of patients were males (92.4%) in
their 50s (mean patient age 57.9 years). Most patients
were smokers (78.6%) and drinkers (64.3%). There were
no statistically significant differences in the proportions
of male patients, smokers or drinkers according to ORN
stage. Karnofsky Performance Status was available in 7
Table 1 Patient characteristics
Stage 1 Stage 2 Stage 3 Total p value
Number of patients 5 (35.7%) 3 (21.4%) 6 (42.9%) 14 N/A
Number of males (%) 5 (100%) 2 (66.7%) 6 (100%) 13 (92.4%) p = 0.21∞
Smokers (%) 4 (80%) 3 (100%) 4 (66.7%) 11 (78.6%) p = 0.75∞
Alcohol use 4 (80%) 2 (66.7%) 3 (50%) 9 (64.3%) p = 0.77∞
Mean age, years – – – 54.45 N/A
§KPS (mean ± SD) – – – 88.57 ± 3.78 N/A
∞ Freeman-Halton extension of the Fisher exact probability test.
§ KPS Karnofsky Performance Status (data available in 7 patients, not analyzed).
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tioning individuals.
Tumor characteristics
Tumor characteristics and initial treatment are pre-
sented in Table 2. The majority of tumors were tonsillar
(5 of 14) or tongue (4 of 14) carcinomas, with single
cases of retromolar trigone, parotid gland, soft palate
and buccal mucosa tumors. Pathologically all tumor
were classified as squamous cell carcinomas, excluding
an adenocarcinoma of the parotid gland. A minority of
tumors was early stage (stage II – 35.7%), while the
majority were advanced tumors (stage III, 28.6%, and
stage IV, 35.7%).
ORN severity and modifying factors
All ORN lesions were confined to the mandible (100%).
There were 35.7% stage 1, 21.4% stage 2 and 42.9% stage 3
ORN lesions. ORN severity by stage was not sig-
nificantly associated with gender (p = 0.139), smoking
(p = 0.514), alcohol use (p = 0.583), tumor site (p = 0.381),
T stage (p < 0.429), N stage (p = 0.643), AJCC stageTable 2 Primary tumor site, stage, pathology and initial treat
Primary site Number of patients TNM stage AJCC st
T4N2 IVA
T4N2 IVA




Tongue 4 T3N0 III
T2N2 IVA
T2N1 III
Retromolar trigone 2 T2N0 II
T2N0 II
Parotid gland 1 T2N2 IVA
Soft palate 1 T3N0 III
Buccal mucosa 1 T2N0 II
CCRT concomitant chemoradiotherapy, RT radiotherapy, SCC squamous cell carcino(p = 0.231), or treatment modality (radiation alone,
surgery with adjuvant radiation or adjuvant concomi-
tant chemoradiation, p = 0.163), (Chi-square tests).
The severity of ORN was positively associated with
radiation modality (Table 3), with intensity-modulated
radiotherapy (IMRT) resulting in less severe and conven-
tional radiotherapy leading to more severe ORN cases
(p < 0.015). There was no correlation identified between
radiation dose and severity of ORN. ORN was diagnosed
after an average of 26.85 months from the end of ra-
diotherapy, with a trend (but no statistical significance)
of stage 3 ORN being discovered later.
Adjuvant concomitant chemoradiotherapy was admin-
istered in 3 patients and resulted in stage 2 or 3 diseases.
All patients had appropriate institutional dental screen-
ing, but only in one patient dental procedures were
performed following radiation, and could be implicated as
a culprit of ORN.
Treatment: HBO and surgery
HBO was used in 57.1% of patients as an adjunct to sur-
gical debridement. It was used for all stages of diseasement
age Pathology Initial treatment ORN Stage





SCC Surgery + adjuvant CCRT 2
SCC Surgery + adjuvant RT 1
SCC Surgery + adjuvant CCRT 3
SCC Surgery + adjuvant RT 2
SCC RT 1
SCC RT 1




Table 3 ORN severity in relation to radiation modality, dose and time to diagnosis
Stage 1 Stage 2 Stage 3 p value
Radiation modality ∞ IMRT 4/4 IMRT 3/3 IMRT 1/5 p = 0.03*
Conventional 4/5
Radiation dose (Gy), mean ± SD § 52.5 ± 5 60 ± 0 59 ± 9.86 p = 0.312¶
Average time from radiation to diagnosis in months (range) 6.47 (3.0–12.0) 9.83 (6.0–11.9) 52.35 (9.0–129.6) p = 0.056¶
∞ Modality information is missing on 1 patient with Grade 1 and 1 patient with Grade 3 disease.
§ Dose information missing in 2 patients with Grade 3 and 1 patient with Grade 1 disease.
* Freeman-Halton extension of the Fisher exact probability test.
¶ One-way Analysis of Variance (ANOVA).
IMRT intensity modulated radiation therapy.
SD standard deviation.
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was not sufficient to control the disease.
Antibiotics were almost always employed in the man-
agement of stage 2 and 3 ORN. If there was a delay lead-
ing to definitive surgery, long-term antibiotics were
used. They were stopped after clinical and radiographic
ORN resolution or complete healing after flap recon-
struction. The choice of antibiotics varied, but usually
included Gram-negative coverage for oral pathogens.
Most commonly used antibiotics were (dose for a 70 kg
adult patient): Amoxicillin 500 mg three times per day,
Clindamycin 300 mg four times per day, or Keflex
500 mg four times per day.
Patients, whose disease was not amenable to control
via conservative measures, underwent surgical proce-
dures (Table 5). Most of patients with stage 1 disease
underwent local debridement procedures to the margin
of the healthy tissue. Patients with stage 2 disease had
segmental resections or free tissue transfer recons-
tructions, whereas patients with stage 3 disease under-
went more extensive mandibulectomies and free tissue
transfers.
The complexity of surgical care can be summarized by
the use of free tissue transfers per patient with the spe-
cific stage of ORN (Table 6). None of the patients with
stage 1 disease required free tissue transfers. There were
a total of 2 free flap procedures in 3 patients with stage
2 disease. On the contrary, there were 6 free tissue
transfers in 6 patients with stage 3 disease, including 2
cases, where two simultaneous free flaps were utilized
during a single procedure in either primary or secondary
ORN reconstruction. One flap was required for externalTable 4 Hyperbaric oxygen therapy use by stage
Stage Number of patients receiving HBO therapy





HBO hyperbarix oxygen, N/A not available.skin cover due to markedly contracted soft tissue enve-
lope. The second flap was provided with either a pectoralis
major myocutaneous flap or additional fasciocutaneous
flap based on recipient vessel availability. There were no
flap failures encountered in this series.
Follow up was available for 13 of 14 patients for an
average of over 2 years. There was no evidence of re-
current or residual cancer in any patient. No clinical
evidence of ORN was present in 84% of patients.
Discussion
We present our experience with treating patients with
ORN at two departments at a large urban academic
center in the period of 6 years.
Despite close to a century has passed since the first
description of ORN shortly after the discovery of x-rays,
there is a multitude of controversies on the subject in
the literature, including about its definition and best
management options [1].
Historically, several factors can influence ORN de-
velopment, including the site and size of the tumour,
radiation dose, type of mandibular resection, injury, or
dental extractions, infection, immune deficiencies, and
malnutrition. It is necessary to keep in mind that many
patients with oral cancer have other serious diseases and
have often had a long history of alcohol and tobacco
misuse, which, in combination with malnutrition and
poor oral hygiene, place these patients at higher risk of
developing ORN. In our series, 13 of 14 patients had pri-
mary tumors in the oral cavity. There was no significant
correlation of ORN stage with tumor site, or T, N, or
AJCC stage.
Radiation is the main etiologic factor in the deve-
lopment of ORN, in a dose-dependent manner. The
incidence has decreased over years, from an estimated
15% in 1970s to 0-5% in 2000s. In our series, the inci-
dence rate of ORN was 0.84%.
ORN is rare with conventional radiation doses of less
than 60Gy, while the rate in those irradiated with >60 Gy
is around 12% [8] IMRT can reduce the dose delivered to
the salivary glands and reduce the rate of xerostomia, as
well as other radiation related toxicities. A study from the
Table 5 Surgical procedures for primary tumor and ORN management
Stage Tumor Primary ORN surgery Other ORN surgery
1 T3N0 soft palate N/A N/A
T2N0 retromolar trigone N/A N/A
T4N2 tonsil Local debridement N/A
T2N0 retromolar trigone Local debridement N/A
T3N0 tongue Marginal resection Local debridement, dental procedures
2 T3N0 tongue Mandibular resection, sequestrectomy Sequestrectomy
T2N1 tongue Segmental resection, FFF Iliac crest bone graft
T4N2 tonsil Segmental resection, osteocutaneous lat dorsi and parascapular free flap N/A
3 T2N2 tongue Sequestrectomy and saucerisation Mandibular resection; Re-resection, FFF,
pectoralis major flap
T2N2 parotid Partial mandibulectomy, FFF RFFF
T4N1 tonsil Mandibulectomy, FFF, pectoralis major flap Iliac crest bone graft
T2N0 tonsil Mandibular resection, reconstructive plate N/A
T2N0 tonsil Segmental resection, reconstructive plate Replacement plate, iliac crest bone graft
T2N0 buccal mucosa Marginal resection Local debridement
ALT anterolateral thigh free flap, FFF fibula osteocutaneous free flap, N/A not available, ORN osteoradionecrosis, RFFF radial forearm free flap.
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mandible at a median follow-up of 34 months after IMRT
for head and neck cancer, using a strict prophylactic
dental care policy [9]. A recent study from the Memorial
Sloan-Kettering Cancer Center showed that ORN is rare
with the use of IMRT [10]. Similar results were found in
another European study [11]. In a review of 18-year litera-
ture evaluating the impact of cancer therapies on preva-
lence of ORN, Peterson et al. reported a weighted ORN
prevalence of 7.4% for conventional radiotherapy, 5.1% for
IMRT, 6.8% for chemoradiotherapy and 5.3% for brachy-
therapy [12].
It can be extrapolated that IMRT would also result in
less severe cases of ORN, when it does develop. In this
study, IMRT was associated with less severe ORN stage
compared to conventional radiotherapy. There was no
correlation identified between radiation dose and sever-
ity of ORN, presumably due to the small number of
patients in the study.
Treatment of ORN is a challenging problem. There
are a variety of treatment options, and no universal
approach to management, as this depends on institu-







Total # flaps per
total # patients
per stage
1 0 0 0/5
2 2 0 2/3
3 3 (1) 3 (1) 6/6and Neck and Oral Maxillofacial Surgeons together
manage patients with ORN.
A treatment that has been in the center of much con-
troversy is HBO. In 1985, Marx developed both a classi-
fication scheme and a treatment protocol for ORN
based on the number and sequence of HBO dives [3,13].
This protocol has been used with variable success in
many studies. An analysis of evidence of the manage-
ment of ORN of the mandible demonstrated that HBO
continues to be used as an adjunct in the management
of ORN, while its clinical usefulness remains controver-
sial [6]. HBO alone has minimal if any benefit in the
treatment of advanced ORN [7].
An updated Cochrane review on HBO for the treat-
ment of the late effects of radiotherapy found some
evidence that HBO therapy is more likely to achieve
mucosal coverage with ORN (RR 1.3; 95% CI 1.1 to 1.6,
P = 0.003) [14]. Single studies included in this review
demonstrated a significantly increased chance of im-
provement or cure for HBO therapy following both
surgical flaps and hemi-mandibulectomy, while there
was also a significantly improved probability of healing
irradiated tooth sockets following dental extraction.
In our series, HBO was employed along with surgical
debridement in the management of 8 of 14 patients,
with all stages of disease. Ultimately, in the majority of
cases, HBO in combination with debridement did not
prevent the progression of disease in stage 2 and 3
patients, who required extensive surgical procedures to
control the disease.
Management of stage 2 disease remains of most
significant interest. Stage 2 is defined as exposed alveolar
Figure 1 An outline of the treatment algorithm by stage of osteoradionecrosis (ORN).
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sequestrectomy or saucerization. There were 3 patients
in stage 2 ORN in our series. All of them were treated
with adjuvant IMRT at 60 Gy. In this series, decisions to
treat by either sequestrectomy or free tissue transfer
were dictated by disease extent. A patient with T3NO
oral tongue cancer had two areas of exposed alveolar
bone, which did not bleed with manipulation. He was
treated with marginal mandibular resection and seques-
trectomy, followed by postoperative HBO, to which he
responded. The second patient with T2N1 tongue cancer
had significant exposed alveolar bone without pathologic
fracture. He was in significant pain and had pronounced
facial edema. A decision was made to perform a segmental
mandibular resection and fibular osteocutaneous free flap
reconstruction, as it was feared that this patient would not
respond to local procedures. Finally, the third patient with
stage 2 disease had T4N2 tonsillar squamous cell car-
cinoma. He had an infected non-union and persistent
oro-cutaneous fistula. Given the amount of involvement,
segmental resection of the mandible and reconstruction
with a mandibular place and osteocutaneous latissimus
dorsi and parascapular free flaps were undertaken.
Jacobson et al. have recently summarized the paradigm
shifts in the ORN management [7]. Importantly, they
have emphasized the conservative approach to manage-
ment of stage 1 disease, while treatment with antibiotics,
transoral debridement or sequestrectomy, and HBO
therapy was reserved for stage 2 disease. Patients with
stage 3 disease are treated aggressively by surgical resec-
tion of all diseased hard and soft tissue and immediate
reconstruction with free tissue transfer.
Surgical treatment of patients in our series closely
followed these principles. Our approach to ORN treat-
ment is summarized in Figure 1. The majority of
patients with stage 1 ORN were treated conservatively
and with local debridement. Surgical care escalated to
sequestrectomy and marginal resection with recons-
truction in stage 2 patients. Most patients with stage 3disease underwent radical excision of ORN with free
tissue reconstruction. Of note, several patients with stage
3 disease required a second flap, which in 2 cases was a
simultaneously performed two free flap procedures.
Expectedly, the number of free flaps used increased corre-
sponding to disease stage.Conclusions
We advocate an aggressive approach to the treatment of
ORN with liberal use of resection of diseased bone and
reconstruction with vascularized free tissue transfer. In
our experience and in agreement with the recent lite-
rature, HBO alone was not sufficient to control ORN
progression. In a few of the most advanced cases, two
simultaneous flaps were required to provide a vascu-
larized bed after radical resection of all diseased tissues,
and to provide soft tissue coverage and reduce tension
across suture lines to avoid venous congestion in the
microvasculature.
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